Undisclosed PD1-IFNα fusion protein / Innovent Biologics - LARVOL DELTA

A PD1-IFNα fusion protein, with an attenuated IFNα fused to a clinically validated PD1 mAb, elicited PD1-dependent IFNα signaling and superior anti-tumor efficacy (AACR 2025) - "Here, we engineered a PD1-IFNα fusion protein composed of a functionally attenuated IFNα and a clinically validated PD1 mAb, Sintilimab, aiming to specifically stimulate PD1-positive immune cells. This PD1-IFNα fusion protein showed favorable pharmacokinetics profile in mice and drug developability. Together, our pre-clinical data demonstrated that a bifunctional PD1-IFNα fusion protein elicits robust PD1/PDL1 signaling blockade and PD1-dependent IFNα signaling activation to achieve anti-tumor efficacy, with potential to expand the benefits of ICB therapies to more cancer patients."

Clinical • Colorectal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CTLA4 • IFNA1 • IL2

Topic: A PD1-IFNα fusion protein, with an attenuated IFNα fused to a clinically validated PD1 mAb, elicited PD1-dependent IFNα signaling and superior anti-tumor efficacy (PRNewswire) - "Innovent Biologics...announces that preclinical data...from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025....Preclinical studies demonstrate superior anti-tumor efficacy compared to PD1 mAb alone in multiple mouse syngeneic tumor models, with undetectable toxicity and a favorable pharmacokinetics profile. This bi-functional molecule potentially benefits patients with ICB-refractory cancers including pancreatic, ovarian, and MSS colorectal cancers."

Preclinical • Colorectal Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting (PRNewswire) - "Innovent Biologics...announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025."

Preclinical • Oncology